Opinion | January 13, 2022
Outlook for the Indian Pharma Industry remains stable for this year
The stability is led by healthy demand in the domestic and emerging markets
The stability is led by healthy demand in the domestic and emerging markets
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore
Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastrointestinal ulcer when a rapid effect is desired or when oral medication is not tolerated
The company has operations in North America, Asia, and Europe,
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Subscribe To Our Newsletter & Stay Updated
